Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Celcuity | 2025 | Post Ipo Debt | $500.0M | Hamel |
| Mineralys Therapeutics | 2025 | Post Ipo Equity | $287.5M | Radnor |
| Reframe Systems | 2025 | Series A | $20.0M | Andover |
| Plexium | 2025 | Series C | $60.1M | San Diego |
| Incyclix Bio | 2025 | Series B | $11.2M | Durham |
| Arvinas | 2025 | Post Ipo Equity | Undisclosed | New Haven |
| Superluminal Medicines | 2025 | Corporate Round | Undisclosed | Boston |
| CANbridge Pharmaceuticals | 2025 | Post Ipo Equity | $12.7M | Beijing |
| Iterum Therapeutics | 2025 | Post Ipo Equity | $2.2M | Dublin |
| Pahr Therapeutics | 2025 | Seed | $14.0M | Boston |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 226 | Celcuity | Post Ipo Debt | $500.0M | Hamel, United States |
| 227 | Mineralys Therapeutics | Post Ipo Equity | $287.5M | Radnor, United States |
| 228 | Reframe Systems | Series A | $20.0M | Andover, United States |
| 229 | Plexium | Series C | $60.1M | San Diego, United States |
| 230 | Incyclix Bio | Series B | $11.2M | Durham, United States |
| 231 | Arvinas | Post Ipo Equity | Undisclosed | New Haven, United States |
| 232 | Superluminal Medicines | Corporate Round | Undisclosed | Boston, United States |
| 233 | CANbridge Pharmaceuticals | Post Ipo Equity | $12.7M | Beijing, China |
| 234 | Iterum Therapeutics | Post Ipo Equity | $2.2M | Dublin, Ireland |
| 235 | Pahr Therapeutics | Seed | $14.0M | Boston, United States |
Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Robotic microfactories for building net-zero homes 2x faster, 2x cheaper with 10x lower carbon
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .
Iterum Therapeutics is a clinical-stage pharmaceutical company that develops significantly differentiated anti-infectives.
Pahr Therapeutics is a clinical stage business, is to create innovative ways to treat pulmonary arterial hypertension.
Spyglass Pharma provides medicine for ophthalmic diseases.
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.
Abcuro develops immunotherapies to treat autoimmunity and cancer.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.
Be Biopharma develops engineered B cell medicines for serious genetic diseases.
RA Capital Management has invested in 369 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics. The firm invests across 18 different industry categories.
Among tracked funding rounds, Celcuity received $500.0M in a Post Ipo Debt round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 369 companies.
Recent RA Capital Management portfolio additions include Celcuity, Mineralys Therapeutics, Reframe Systems, Plexium, Incyclix Bio. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors